AU2013306018B2 - Haptens of olanzapine - Google Patents
Haptens of olanzapine Download PDFInfo
- Publication number
- AU2013306018B2 AU2013306018B2 AU2013306018A AU2013306018A AU2013306018B2 AU 2013306018 B2 AU2013306018 B2 AU 2013306018B2 AU 2013306018 A AU2013306018 A AU 2013306018A AU 2013306018 A AU2013306018 A AU 2013306018A AU 2013306018 B2 AU2013306018 B2 AU 2013306018B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- compound
- methyl
- carrier
- immunogenic carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691454P | 2012-08-21 | 2012-08-21 | |
| US61/691,454 | 2012-08-21 | ||
| PCT/US2013/055700 WO2014031587A1 (en) | 2012-08-21 | 2013-08-20 | Haptens of olanzipine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013306018A1 AU2013306018A1 (en) | 2015-03-12 |
| AU2013306018B2 true AU2013306018B2 (en) | 2017-08-10 |
Family
ID=49081007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013306018A Active AU2013306018B2 (en) | 2012-08-21 | 2013-08-20 | Haptens of olanzapine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9303041B2 (enExample) |
| EP (2) | EP2888269B1 (enExample) |
| JP (3) | JP6171014B2 (enExample) |
| CN (1) | CN104854110B (enExample) |
| AU (1) | AU2013306018B2 (enExample) |
| CA (1) | CA2882454C (enExample) |
| ES (2) | ES2701062T3 (enExample) |
| PL (1) | PL2888269T3 (enExample) |
| PT (1) | PT2888269T (enExample) |
| TR (1) | TR201816378T4 (enExample) |
| WO (1) | WO2014031587A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015529199A (ja) | 2012-08-21 | 2015-10-05 | オルソ−クリニカル ダイアグノスティクス，インコーポレイティド | パリペリドンハプテンに対する抗体及びその使用 |
| ES2701062T3 (es) * | 2012-08-21 | 2019-02-20 | Janssen Pharmaceutica Nv | Haptenos de olanzapina |
| EP2888277A4 (en) | 2012-08-21 | 2016-05-18 | Ortho Clinical Diagnostics Inc | ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF |
| AU2013305970B2 (en) | 2012-08-21 | 2017-08-17 | Saladax Biomedical Inc. | Antibodies to aripiprazole haptens and use thereof |
| WO2014031645A1 (en) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc | Antibodies to risperidone haptens and use thereof |
| ES2654413T3 (es) | 2012-08-21 | 2018-02-13 | Janssen Pharmaceutica, N.V. | Anticuerpos a quetiapina y uso de los mismos |
| WO2014031584A1 (en) | 2012-08-21 | 2014-02-27 | Janssen Pharmaceutica Nv | Haptens of aripiprazole and their use in immunoassays |
| WO2014031662A2 (en) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc | Antibodies to olanzapine and use thereof |
| ES3057437T3 (en) | 2012-08-21 | 2026-03-02 | Janssen Pharmaceutica Nv | Antibodies to olanzapine haptens and use thereof |
| PL2888286T3 (pl) | 2012-08-21 | 2018-07-31 | Janssen Pharmaceutica Nv | Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie |
| ES2870004T3 (es) | 2012-08-21 | 2021-10-26 | Janssen Pharmaceutica Nv | Anticuerpos contra la risperidona y uso de los mismos |
| PL2888373T3 (pl) | 2012-08-21 | 2018-08-31 | Janssen Pharmaceutica Nv | Przeciwciała dla arypiprazolu i ich zastosowanie |
| CN108368180B (zh) | 2015-12-17 | 2022-07-26 | 詹森药业有限公司 | 喹硫平的抗体及其用途 |
| JP6949025B2 (ja) | 2015-12-17 | 2021-10-13 | ヤンセン ファーマシューティカ エヌ．ベー． | リスペリドンに対する抗体及びその使用 |
| CN110938082A (zh) * | 2019-10-30 | 2020-03-31 | 杭州博拓生物科技股份有限公司 | 一种奥氮平人工抗原及其制备方法 |
| CN110950808A (zh) * | 2019-10-30 | 2020-04-03 | 杭州博拓生物科技股份有限公司 | 一种氯氮平人工抗原及其制备方法 |
| EP4267187A1 (en) * | 2020-12-22 | 2023-11-01 | Intervet International B.V. | Conjugated zearalenone to protect against mycotoxicosis |
| CN114685477B (zh) * | 2020-12-25 | 2023-11-17 | 长沙博源医疗科技有限公司 | 一种利奈唑胺衍生物、免疫原、抗利奈唑胺特异性抗体及其制备方法与应用 |
| CN114685527B (zh) * | 2020-12-25 | 2024-03-05 | 长沙博源医疗科技有限公司 | 一种奥氮平衍生物、免疫原、抗奥氮平特异性抗体及其制备方法与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014895A1 (en) * | 2002-08-05 | 2004-02-19 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022780A (en) | 1973-03-06 | 1977-05-10 | Imperial Chemical Industries Limited | Process for the manufacture of indole derivatives |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US6034078A (en) | 1992-05-29 | 2000-03-07 | Eli Lilly And Company Limited | Thienobenzodiazepine compounds |
| DE69329887T2 (de) * | 1992-05-29 | 2001-05-23 | Eli Lilly And Co., Ltd. | Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems |
| EP0576095B1 (en) * | 1992-06-26 | 1999-01-27 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassays with labeled thyronine hapten analogues |
| US5395933A (en) * | 1992-08-07 | 1995-03-07 | Eastman Kodak Company | Carbamazepine hapten analogues |
| UA76708C2 (uk) * | 1999-12-08 | 2006-09-15 | Сінгента Патисипейшонс Аг | Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду |
| US6958156B2 (en) | 2000-12-15 | 2005-10-25 | Vyrex Corporation | Isoflavone derivatives |
| EP1492794B1 (en) * | 2002-03-28 | 2007-12-12 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| PT1664007E (pt) * | 2003-09-23 | 2010-02-15 | Fermion Oy | Preparação de quetiapina |
| TW200616604A (en) * | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| AU2005281359A1 (en) * | 2004-08-26 | 2006-03-16 | Apparao Satyam | Prodrugs and codrugs containing novel bio-cleavable disulfide linkers |
| JP2010540920A (ja) * | 2007-09-27 | 2010-12-24 | ノバルティス アーゲー | 薬物モニタリングアッセイ |
| WO2010033270A1 (en) | 2008-09-17 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors |
| TW201020258A (en) | 2008-10-14 | 2010-06-01 | Astrazeneca Ab | Chemical compounds 542 |
| EP2194048A1 (en) | 2008-12-02 | 2010-06-09 | Dirk Sartor | Nitrate esters for the treatment of vascular and metabolic diseases |
| CN107714703A (zh) | 2009-12-31 | 2018-02-23 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
| RS58335B1 (sr) | 2010-03-11 | 2019-03-29 | Kempharm Inc | Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena |
| US8088594B2 (en) * | 2010-03-16 | 2012-01-03 | Saladax Biomedical Inc. | Risperidone immunoassay |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| US8623324B2 (en) | 2010-07-21 | 2014-01-07 | Aat Bioquest Inc. | Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates |
| JP5757497B2 (ja) * | 2010-10-06 | 2015-07-29 | 公立大学法人大阪府立大学 | シガトキシン類ｃｔｘ１ｂおよび５４−デオキシ−ｃｔｘ１ｂを認識するモノクローナル抗体およびそれを用いるシガトキシン類検出キット |
| WO2013088255A1 (en) | 2011-12-15 | 2013-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
| ES2701062T3 (es) * | 2012-08-21 | 2019-02-20 | Janssen Pharmaceutica Nv | Haptenos de olanzapina |
-
2013
- 2013-08-20 ES ES13753774T patent/ES2701062T3/es active Active
- 2013-08-20 TR TR2018/16378T patent/TR201816378T4/tr unknown
- 2013-08-20 EP EP13753774.2A patent/EP2888269B1/en active Active
- 2013-08-20 CN CN201380054963.3A patent/CN104854110B/zh active Active
- 2013-08-20 US US13/970,653 patent/US9303041B2/en active Active
- 2013-08-20 WO PCT/US2013/055700 patent/WO2014031587A1/en not_active Ceased
- 2013-08-20 PL PL13753774T patent/PL2888269T3/pl unknown
- 2013-08-20 EP EP18202081.8A patent/EP3492473B1/en active Active
- 2013-08-20 ES ES18202081T patent/ES3043017T3/es active Active
- 2013-08-20 PT PT13753774T patent/PT2888269T/pt unknown
- 2013-08-20 JP JP2015528568A patent/JP6171014B2/ja active Active
- 2013-08-20 CA CA2882454A patent/CA2882454C/en active Active
- 2013-08-20 AU AU2013306018A patent/AU2013306018B2/en active Active
-
2017
- 2017-07-03 JP JP2017130471A patent/JP6423490B2/ja active Active
-
2018
- 2018-10-18 JP JP2018196525A patent/JP6763000B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014895A1 (en) * | 2002-08-05 | 2004-02-19 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6423490B2 (ja) | 2018-11-14 |
| JP2017222671A (ja) | 2017-12-21 |
| ES2701062T3 (es) | 2019-02-20 |
| CA2882454A1 (en) | 2014-02-27 |
| JP2015532645A (ja) | 2015-11-12 |
| PT2888269T (pt) | 2019-01-17 |
| JP2019034955A (ja) | 2019-03-07 |
| CA2882454C (en) | 2020-08-11 |
| EP3492473A1 (en) | 2019-06-05 |
| US9303041B2 (en) | 2016-04-05 |
| EP2888269A1 (en) | 2015-07-01 |
| CN104854110B (zh) | 2016-12-28 |
| CN104854110A (zh) | 2015-08-19 |
| US20140213766A1 (en) | 2014-07-31 |
| WO2014031587A1 (en) | 2014-02-27 |
| HK1211933A1 (en) | 2016-06-03 |
| AU2013306018A1 (en) | 2015-03-12 |
| EP3492473B1 (en) | 2025-07-30 |
| TR201816378T4 (tr) | 2018-11-21 |
| ES3043017T3 (en) | 2025-11-24 |
| JP6171014B2 (ja) | 2017-07-26 |
| PL2888269T3 (pl) | 2019-06-28 |
| EP2888269B1 (en) | 2018-10-24 |
| JP6763000B2 (ja) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2888269B1 (en) | Haptens of olanzapine | |
| AU2018200435B2 (en) | Antibodies to olanzapine haptens and use thereof | |
| CA2882557C (en) | Haptens of quetiapine for use in immunoassays | |
| EP3415516B1 (en) | Haptens of risperidone and paliperidone | |
| HK40009713A (en) | Haptens of olanzipine | |
| HK40018877A (en) | Antibodies to olanzapine haptens and use thereof | |
| HK1211933B (en) | Haptens of olanzipine | |
| HK1253809A1 (en) | Haptens of quetiapine for use in immunoassays | |
| HK1253809B (en) | Haptens of quetiapine for use in immunoassays | |
| HK1211931B (en) | Haptens of quetiapine for use in immunoassays | |
| HK1211857B (en) | Antibodies to olanzapine haptens and use thereof | |
| HK40002082A (en) | Haptens of risperidone and paliperidone | |
| HK40002082B (en) | Haptens of risperidone and paliperidone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HAPTENS OF OLANZAPINE |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: JANSSEN PHARMACEUTICA NV Free format text: FORMER APPLICANT(S): ORTHO-CLINICAL DIAGNOSTICS, INC; JANSSEN PHARMACEUTICA NV |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: SALADAX BIOMEDICAL INC. Free format text: FORMER OWNER(S): JANSSEN PHARMACEUTICA NV |